TerraCoV2 vaccine - Oragenics
Alternative Names: SARS-CoV-2 Vaccine - Oragenics; Terra CoV-2 - Oragenics; TerraCoV2 vaccine - Noachis TerraLatest Information Update: 28 Jun 2024
At a glance
- Originator National Institute of Allergy and Infectious Diseases
- Developer National Research Council Canada; Noachis Terra; Oragenics Inc
- Class Adjuvants; COVID-19 vaccines; Protein vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Intranasal)
- 21 Dec 2021 Oragenics extends licensing and collaboration agreement with National Research Council of Canada to develop vaccine for COVID-2019 infections (Omicron variant)
- 01 Dec 2021 Oragenics expects to file an IND for COVID-19 infection, in the second quarter of 2022